San Francisco, CA, United States of America

Keith G Duncan

This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignee: University of California. Active years: 2008.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Keith G Duncan. Retrieved from https://idiyas.com/inventor/keith-g-duncan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 14(Granted Patents)


Company Filing History:


Years Active: 2008

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Inventor Keith G Duncan

Introduction

Keith G Duncan is an accomplished inventor based in San Francisco, CA. He has made significant contributions to the field of medical research, particularly in the treatment of age-related macular degeneration. With a total of 2 patents, Duncan's work focuses on innovative methods to enhance visual function and address retinal health.

Latest Patents

Duncan's latest patents include groundbreaking inventions aimed at improving the treatment of age-related macular degeneration. The first patent, titled "Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)," addresses the treatment of this condition by regulating pathogenic mechanisms similar to atherosclerosis. This invention utilizes compositions that increase reverse cholesterol transport as therapeutic targets. A specific embodiment of this patent involves reducing the lipid content of the retinal pigment epithelium and/or Bruch's membrane by delivering Apolipoprotein A1, particularly a mimetic peptide.

The second patent, "Treatment for dark adaptation," also targets age-related macular degeneration and aims to assist individuals with impaired visual function, such as difficulties in dark adaptation. Similar to his first patent, this invention employs compositions that enhance reverse cholesterol transport. It also focuses on reducing lipid content in the retinal pigment epithelium and/or Bruch's membrane through the delivery of Apolipoprotein A1.

Career Highlights

Keith G Duncan is affiliated with the University of California, where he conducts his research and develops his innovative solutions. His work has garnered attention for its potential to significantly improve the quality of life for individuals suffering from visual impairments.

Collaborations

Duncan collaborates with notable colleagues, including Kathy R Bailey and Brian Y Ishida, who contribute to his research efforts and help advance his innovative projects.

Conclusion

Keith G Duncan's contributions to the field of medical research through his patents demonstrate his commitment to improving visual health. His innovative approaches to treating age-related macular degeneration highlight the importance of research in developing effective therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…